STAT

3 China biotech stories to watch in 2019

In 2018, biotech in China generated relentless news. What's next for 2019?

As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here

This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readSociety
Mental Health Care Accounts For A Growing Number Of Private Insurance Claims, Report Finds
Mental health care is accounting for a growing number of private insurance claims, according to a new report.
STAT1 min readWellness
Listen: Drug Pricing Partisanship, Tech’s March Into Health Care, And Tinder For Clinical Trials
Has drug price reform already stalled? How far has tech come in medicine? All that and more on the new episode of our #biotech #podcast, "The Readout LOUD."
STAT4 min readPolitics
In Washington, A Partisan Approach To Lowering Drug Costs Leaves Democrats Doubting Their Own Party Leadership
Even some Democratic lawmakers are questioning Speaker Pelosi’s strategy to couple legislation to lower prescription drug costs with far more contentious Obamacare bills.